Wird geladen...

Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon

BACKGROUND. The use of immunotherapeutic agents, specifically immune checkpoint inhibitors (ICIs) for solid malignancies, is rapidly rising, and many new agents and treatment combinations are in development. However, ICIs have a unique side-effect profile of immune-related adverse events (irAEs) com...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ann Surg Oncol
Hauptverfasser: Helmink, Beth A., Roland, Christina L., Kiernan, Colleen M., Wargo, Jennifer A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2020
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7594106/
https://ncbi.nlm.nih.gov/pubmed/31965370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-019-08183-0
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!